What To Expect When Johnson & Johnson Unveils Q4 Performance This Month

For Johnson & Johnson JNJWells Fargo sees in-line Q4 FY21 despite incremental omicron headwind and underlying growth guidance for FY22 but conservative EPS. 

  • The analyst has lowered the Q4 sales forecast by $134 million, to $24.9 billion (vs. consensus of $25.1 billion), primarily due to lower FX tailwind, representing 12.5% adjusted operational growth (+4.7% ex-vaccine).
  • Q4 EPS estimate remains unchanged at $2.14, slightly below the consensus of $2.16. 
  • For FY22, Wells Fargo anticipates JNJ guiding conservatively, with 4-5% adjusted operational sales growth (ex-COVID vaccine) and ex-FX EPS growth of 5-6%. 
  • Also See: Johnson & Johnson To Spin-Off Consumer Health Business: What You Need To Know.
  • COVID vaccine represents potential multi-billion sales upside to their current model but is not expected to impact the bottom line materially, notes Wells Fargo.
  • The analyst models 2022 adjusted operational sales growth of 3.4%, or +6.1% ex-vaccine, and EPS of $10.19, below the consensus of $10.38, reflecting differences in FX headwind and tax rate assumptions.
  • Wells Fargo anticipates modest softness in JNJ's Q4 Medical Device sales. It sees medical device sales of $6.9 billion, or 6.0% adjusted operational growth.
  • The analyst forecast Q4 consumer segment sales of $3.7 billion or up 2.8% adjusted operational Y/Y.
  • Price Action: JNJ shares are down 0.79% at $167.41 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorBiotechEarningsNewsGuidanceHealth CareAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!